Elucidata leverages its platform, Polly to augment the quality of data in pre-clinical drug discovery. It curates multi-omics and assay data to make them ML-ready or analysis-ready. Our exceptional multi-disciplinary team of experts use Polly's powerful curation engine to harmonize a diverse array of data-types, curate metadata and process data consistently at affordable costs while maintaining information-richness. We are one of the only companies to offer a tech-enabled approach to multi-modal data curation that serves the life science industry. Polly's technology and experts have helped R&D teams arrive at multiple validated drug targets across immunology, oncology, and metabolomic disorders. Currently, 25+ research organizations, including 4 of the largest 10 pharma companies are using Polly and its allied solutions to accelerate their discovery programs. Many other data-driven healthcare companies also use Polly to process, harmonize and store public or in-house biomedical data.
Phone No: 9716140329
Contact Email: info@elucidata.io
  • 114 Sansome Street, Suite 250 San Francisco, CA 94104
  • JoinedJune 25, 2024



Stories by Elucidata Corporation
Data Processing Pipelines for RNA-seq Data by elucidata
Data Processing Pipelines for RNA...
RNA sequencing (RNA-seq) provides insights into gene expression levels, alternative splicing events, and the...
ranking #965 in data See all rankings
Multi-omics: Opportunities, Challenges and Applications in Biomarker Discovery by elucidata
Multi-omics: Opportunities, Challe...
Biomarker discovery holds immense potential to revolutionize healthcare by providing insights into disease me...
Role of MLOps in Biomedical Research by elucidata
Role of MLOps in Biomedical Resear...
Biomedical Research with its cutting edge innovations and futuristic outlook can positively utilize MLOps for...
ranking #3 in biomedical See all rankings